TIP24-199: Rhenium (Re-186) Obisbemeda {Re-186-Nanoliposome (186RNL)} in Leptomeningeal Metastases [LM] Phase 1/2A Dose Escalation Trial: Update of Initial Safety and Feasibility Through Cohorts 1–4 | Synapse

⌘+K

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1OCTS-11 PHASE 1 DOSE ESCALATION OF RHENIUM (186RE) OBISBEMEDA (RHENIUM NANOLIPOSOME,186RNL FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES (LM): ONGOING CLINICAL STUDY UPDATE FOR INITIAL SAFETY AND FEASIBILITY2024
2Abstract PD13-04: Rhenium (186Re) obisbemeda (rhenium nanoliposome,186RNL) for the treatment of leptomeningeal metastases (LM): Phase 1 dose escalation study resultsEarly-Phase Clinical Trial · 2026
3CTSI-06 PHASE 1 DOSE ESCALATION OF RHENIUM (186RE) OBISBEMEDA (RHENIUM NANOLIPOSOME,186RNL (REYOBIQ) FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES (LM): CLINICAL STUDY RESULTS FOR SAFETY AND EFFICACY2025
4CTNI-43. PHASE 1/2 RESPECT-GBM TRIAL OF RHENIUM (186RE) OBISBEMEDA IN RECURRENT GLIOBLASTOMA: SAFETY AND EFFICACY FROM THE PHASE 1 AND UPDATE ON PHASE 22025
5RMTD-08 RADIATION ABSORBED DOSE TO SPINAL CORD: THERAPY OF LEPTOMENINGEAL METASTASES USING BETA-EMISSION RADIOPHARMACEUTICALS2024

More from Journal of the National Comprehensive Cancer Network

More from The University of Texas MD Anderson Cancer Center